TY - JOUR
T1 - Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention
T2 - Insights from the ATLANTIC trial
AU - Fabris, Enrico
AU - Van't Hof, Arnoud
AU - Hamm, Christian W.
AU - Lapostolle, Frédéric
AU - Lassen, Jens Flensted
AU - Goodman, Shaun G.
AU - Ten Berg, Jurriën M.
AU - Bolognese, Leonardo
AU - Cequier, Angel
AU - Chettibi, Mohamed
AU - Hammett, Christopher J.
AU - Huber, Kurt
AU - Janzon, Magnus
AU - Merkely, Béla
AU - Storey, Robert F.
AU - Zeymer, Uwe
AU - Cantor, Warren J.
AU - Rousseau, Hélène
AU - Vicaut, Eric
AU - Montalescot, Gilles
N1 - Publisher Copyright:
© Europa Digital & Publishing 2017. All rights reserved.
PY - 2017/5/15
Y1 - 2017/5/15
N2 - Aims: The aim of this study was to identify predictors of complete ST-segment resolution (STR) pre-primary percutaneous coronary intervention (PCI) in patients enrolled in the ATLANTIC trial. Methods and results: ECGs recorded at the time of inclusion (pre-hospital [pre-H]-ECG) and in the catheterisation laboratory before angiography (pre-PCI-ECG) were analysed by an independent core laboratory. Complete STR was defined as ≥70%. Complete STR occurred pre-PCI in 12.8% (204/1, 598) of patients and predicted lower 30-day composite MACCE (OR=0.10, 95% CI: 0.002-0.57, p=0.001) and total mortality (OR=0.16, 95% CI: 0.004-0.95, p=0.035). Independent predictors of complete STR included the time from index event to pre-H-ECG (OR=0.94, 95% CI: 0.89-1.00, p=0.035), use of heparins before pre- PCI-ECG (OR=1.75, 95% CI: 1.25-2.45, p=0.001) and time from pre-H-ECG to pre-PCI-ECG (OR=1.09, 95% CI: 1.03-1.16, p=0.005). In the pre-H ticagrelor group, patients with complete STR had a significantly longer delay between pre-H-ECG and pre-PCI-ECG compared to patients without complete STR (median 53 [44-73] vs. 49 [38.5-61] mins, p=0.001); however, this was not observed in the control group (in-hospital ticagrelor) (50 [40-67] vs. 49 [39-61] mins, p=0.258). Conclusions: Short patient delay, early administration of anticoagulant and ticagrelor if a long transfer delay is expected may help to achieve reperfusion prior to PCI. Pre-H treatment may be beneficial in patients with longer transfer delays, allowing the drug to become biologically active. ClinicalTrials.gov Identifier: NCT01347580.
AB - Aims: The aim of this study was to identify predictors of complete ST-segment resolution (STR) pre-primary percutaneous coronary intervention (PCI) in patients enrolled in the ATLANTIC trial. Methods and results: ECGs recorded at the time of inclusion (pre-hospital [pre-H]-ECG) and in the catheterisation laboratory before angiography (pre-PCI-ECG) were analysed by an independent core laboratory. Complete STR was defined as ≥70%. Complete STR occurred pre-PCI in 12.8% (204/1, 598) of patients and predicted lower 30-day composite MACCE (OR=0.10, 95% CI: 0.002-0.57, p=0.001) and total mortality (OR=0.16, 95% CI: 0.004-0.95, p=0.035). Independent predictors of complete STR included the time from index event to pre-H-ECG (OR=0.94, 95% CI: 0.89-1.00, p=0.035), use of heparins before pre- PCI-ECG (OR=1.75, 95% CI: 1.25-2.45, p=0.001) and time from pre-H-ECG to pre-PCI-ECG (OR=1.09, 95% CI: 1.03-1.16, p=0.005). In the pre-H ticagrelor group, patients with complete STR had a significantly longer delay between pre-H-ECG and pre-PCI-ECG compared to patients without complete STR (median 53 [44-73] vs. 49 [38.5-61] mins, p=0.001); however, this was not observed in the control group (in-hospital ticagrelor) (50 [40-67] vs. 49 [39-61] mins, p=0.258). Conclusions: Short patient delay, early administration of anticoagulant and ticagrelor if a long transfer delay is expected may help to achieve reperfusion prior to PCI. Pre-H treatment may be beneficial in patients with longer transfer delays, allowing the drug to become biologically active. ClinicalTrials.gov Identifier: NCT01347580.
KW - Adjunctive pharmacotherapy
KW - Clinical research
KW - Clinical trials
KW - ST-elevation myocardial infarction (STEMI)
KW - Angioplasty, Balloon, Coronary/adverse effects
KW - Percutaneous Coronary Intervention/adverse effects
KW - Platelet Aggregation Inhibitors/therapeutic use
KW - Humans
KW - Middle Aged
KW - Risk Factors
KW - Male
KW - Treatment Outcome
KW - Thrombolytic Therapy/methods
KW - Emergency Medical Services/methods
KW - Electrocardiography/methods
KW - Aged, 80 and over
KW - Female
KW - Aged
KW - Myocardial Infarction/therapy
U2 - 10.4244/EIJ-D-16-00965
DO - 10.4244/EIJ-D-16-00965
M3 - Journal article
C2 - 28134127
AN - SCOPUS:85019888130
SN - 1774-024X
VL - 13
SP - 69
EP - 77
JO - EuroIntervention
JF - EuroIntervention
IS - 1
ER -